So Isis and their partner Sanofi have received FDA approval for mipomersen (branded as Kynamro). Late last year, the European Medicines Agency turned them down, which has people wondering about the drug's future, but here they are, albeit with a warning on the label about liver toxicity. Mipomersen is designed to lower the Apo-B lipoprotein in people with the most severe (homozygous) form of...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Mipomersen Approved (Bonus Antisense Roundup Included)
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account